ClinicalTrials.gg
Not yet recruitingNCT07890597Updated Nov 10, 2026

A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer

A Phase 3 interventional study of Atirmociclib and giredestrant in Early Breast Cancer and Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-), sponsored by Pfizer. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Updated Nov 10, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing atirmociclib in Breast Neoplasms — 4 open to participants now, 8 under way, 2 of them phase 3. atirmociclib · Breast Neoplasms.

Planned enrollment
Largest of 10
3,800 · median 262
Started
2026
with 1 other
Phase 3
2 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
7 of 10
Pfizer

Among the 10 studies testing atirmociclib in Breast Neoplasms, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 2 in phase 3, and was the 10th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 10 studies testing atirmociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About atirmociclib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing atirmociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This Phase 3 study will evaluate whether atirmociclib plus giredestrant improves invasive breast cancer-free survival compared with giredestrant alone in adults with ER-positive, HER2-negative early breast cancer at medium or high risk of recurrence.

This is a Phase 3, double blind, placebo controlled study of atirmociclib plus giredestrant vs. giredestrant monotherapy as adjuvant treatment in adult patients with ER+, HER2- early breast cancer. The study plans to enroll 3800 participants randomized 1:1 into one of two treatment arms (Arm A - investigational: atirmociclib plus giredestrant taken continuously in a 28-day cycle) or (Arm B - comparator: placebo plus giredestrant taken continuously in a 28-day cycle). Participants may be treated with atirmociclib/placebo up to 3 years and giredestrant up to 5 years followed by long term follow up for survival and evaluation of recurrence of disease.

03

Conditions studied

  • Early Breast Cancer
  • Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)

Browse trials for

Keywords

  • ER+/HR-
  • Adjuvant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

KEY INCLUSION CRITERIA

  1. confirmed unilateral primary adenocarcinoma of the breast

    • ER-positive by local assessment
    • documented -negative
  2. Node positive or node negative as defined by:

    • Pathological node positive (microscopic and/or macroscopic tumor involvement >/=pN1)
    • pN0 and pT >1cm with at least one of the following:

      1. pT4N0 or
      2. histologically Grade 3 disease or
      3. high-risk classification based on genomic assay
  3. Randomization within 16 months of definitive breast surgery
  4. If indicated, completed and/or neoadjuvant chemotherapy, adjuvant radiation therapy >/= 21 days prior to randomization

KEY EXCLUSION CRITERIA

  1. Distant of breast cancer beyond regional lymph nodes
  2. Multicentric or multifocal breast cancer if any tumor foci meet pathologic criteria for ER(-) or HER2(+)
  3. cardiovascular disease or cardiac repolarization abnormality for 6 months prior to randomization; resting heart rate \<50bpm
  4. Has received the following prior systemic anti-cancer therapy for breast cancer

    • prior atirmociclib, giredestrant, other anti-cancer agent
    • prior treatment with olaparib

    NOTES:

    • short course of prior neo/adjuvant CDK4/6 inhibitor treatment (\</=8 weeks) is permitted; 10-day required
    • short course of prior neoadjuvant and/or adjuvant ET (\</=18 weeks) is permitted; 35-day washout period for tamoxifen is required
  5. Prior treatment with investigational product within 30 days or 5 half-lives
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,800 participants (estimated)

Study arms

  • Experimental
    Arm A : Atirmociclib + giredestrant

    Atirmociclib tablet given orally twice daily, plus giredestrant capsule given orally once per day

    Drug: Atirmociclib · Drug: giredestrant

  • Active comparator
    Arm B: Placebo for atirmociclib + giredestrant

    Placebo atirmociclib tablets given orally twice a day plus giredestrant capsule given once a day

    Drug: giredestrant · Other: Atirmociclib placebo

Interventions

  • Atirmociclib tablet given orally twice daily, plus giredestrant capsule given orally once per day

    Also known as: PF-07220060

  • giredestrant capsule given once a day

  • OtherAtirmociclib placebo

    Atirmociclib placebo tablet given twice a day

06

What researchers measure

Primary outcomes

  1. Invasive Breast Cancer Free Survival (iBCFS)

    iBCFS is defined as the time from the date of randomization to the date of first documented occurrence of invasive ipsilateral breast tumor recurrence, local-regional invasive breast cancer recurrence, invasive contralateral breast cancer, distant recurrence, or death from any cause, as determined by investigator assessment per STEEP v2.0 criteria

    Time frame: From randomization to first iBCFS event, up to 16 years

Secondary outcomes

  1. Invasive Disease Free Survival (iDFS)

    iDFS defined as the time from the date of randomization to the date of first documented occurrence of invasive ipsilateral breast tumor recurrence, local-regional invasive breast cancer recurrence, invasive contralateral breast cancer, distant recurrence, second primary invasive non-breast cancer, or death from any cause, as determined by investigator assessment per STEEP v2.0 criteria

    Time frame: From randomization to first iDCFS event, up to 16 years

  2. Disease Recurrence Free Survival (DRFS)

    DRFS as per investigator assessment, defined as the time from the date of randomization to the date of distant recurrence as determined by investigator assessment or death from any cause, whichever occurs first

    Time frame: From randomization to first DRFS event, up to 16 years

  3. Overall survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause

    Time frame: From randomization to death from any cause, up to 16 years

  4. Number and percentage of Participants with Treatment-Emergent Adverse Events (AEs)

    Type, incidence, severity of AE graded by NCI CTCAE v 5.0, seriousness and relationship to study intervention

    Time frame: From start of treatment until 28 days after last dose of study treatment, up to 5 years

  5. Percentage of participants With Clinical Laboratory Abnormalities

    Time frame: From start of treatment until 28 days after last dose of study treatment, up to 5 years

  6. Percentage of Participants With ECG abnormalities

    Time frame: From start of treatment until 28 days after last dose of study treatment, up to 5 years

  7. Patient Reported Outcomes (PRO)

    Change from baseline in participant reported total score, well-being subscales and symptoms scores and TOI per FACT-ES

    Time frame: From start of treatment until 28 days after last dose of study treatment, up to 5 years

  8. Pre-dose Plasma Concentration (Ctrough) of atirmociclib

    Time frame: Cycle 1 Day 15, Cycle 2 Day 1, and Cycle 3 Day 1; Cycle is defined as 28 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2032, 64 months later.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 64 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2026
First posted
Oct 22, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Apr 13, 2032
CompletionEst.
Aug 20, 2042
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 time frame changed, 1 removed
What changed in the outcomes
  • RemovedInvasive Disease Free Survival (iDFS)Time frame: Baseline until recurrence up to 64 months
  • Time frameInvasive Breast Cancer Free Survival (iBCFS)Baseline until recurrence up to 64 months → From randomization to first iBCFS event, up to 16 years
Nov 10, 2026
Secondary outcomes
7 time frame changed, 1 added
What changed in the outcomes
  • AddedInvasive Disease Free Survival (iDFS)Time frame: From randomization to first iDCFS event, up to 16 years
  • Time frameDisease Recurrence Free Survival (DRFS)Baseline until recurrence up to 64 months → From randomization to first DRFS event, up to 16 years
  • Time frameOverall survival (OS)Baseline until recurrence up to 64 months → From randomization to death from any cause, up to 16 years
  • Time frameNumber and percentage of Participants with Treatment-Emergent Adverse Events (AEs)Baseline until recurrence up to 64 months → From start of treatment until 28 days after last dose of study treatment, up to 5 years
  • Time framePercentage of participants With Clinical Laboratory AbnormalitiesBaseline until recurrence up to 64 months → From start of treatment until 28 days after last dose of study treatment, up to 5 years
  • Time framePercentage of Participants With ECG abnormalitiesBaseline until recurrence up to 64 months → From start of treatment until 28 days after last dose of study treatment, up to 5 years
  • Time framePatient Reported Outcomes (PRO)Baseline until recurrence up to 64 months → From start of treatment until 28 days after last dose of study treatment, up to 5 years
  • Time framePre-dose Plasma Concentration (Ctrough) of atirmociclibCycle 1 Day 15, Cycle 2 Day 1, and Cycle 3 Day 1. Cycle is defined as 28 days → Cycle 1 Day 15, Cycle 2 Day 1, and Cycle 3 Day 1; Cycle is defined as 28 days
Nov 10, 2026
Registered
First appeared on the registry
Oct 22, 2026
Show all 2 updates
  1. Nov 10, 2026
    Primary outcomes 1 time frame changed, 1 removed
    What changed in the outcomes
    • RemovedInvasive Disease Free Survival (iDFS)Time frame: Baseline until recurrence up to 64 months
    • Time frameInvasive Breast Cancer Free Survival (iBCFS)Baseline until recurrence up to 64 months → From randomization to first iBCFS event, up to 16 years
    Secondary outcomes 7 time frame changed, 1 added
    What changed in the outcomes
    • AddedInvasive Disease Free Survival (iDFS)Time frame: From randomization to first iDCFS event, up to 16 years
    • Time frameDisease Recurrence Free Survival (DRFS)Baseline until recurrence up to 64 months → From randomization to first DRFS event, up to 16 years
    • Time frameOverall survival (OS)Baseline until recurrence up to 64 months → From randomization to death from any cause, up to 16 years
    • Time frameNumber and percentage of Participants with Treatment-Emergent Adverse Events (AEs)Baseline until recurrence up to 64 months → From start of treatment until 28 days after last dose of study treatment, up to 5 years
    • Time framePercentage of participants With Clinical Laboratory AbnormalitiesBaseline until recurrence up to 64 months → From start of treatment until 28 days after last dose of study treatment, up to 5 years
    • Time framePercentage of Participants With ECG abnormalitiesBaseline until recurrence up to 64 months → From start of treatment until 28 days after last dose of study treatment, up to 5 years
    • Time framePatient Reported Outcomes (PRO)Baseline until recurrence up to 64 months → From start of treatment until 28 days after last dose of study treatment, up to 5 years
    • Time framePre-dose Plasma Concentration (Ctrough) of atirmociclibCycle 1 Day 15, Cycle 2 Day 1, and Cycle 3 Day 1. Cycle is defined as 28 days → Cycle 1 Day 15, Cycle 2 Day 1, and Cycle 3 Day 1; Cycle is defined as 28 days
    + 1 other change: verification date
  2. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07890597
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Apr 13, 2032 (estimated)
Completion
Aug 20, 2042 (estimated)
Last update
Nov 10, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atirmociclib

Start the discussion